Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Background Passive immunotherapy using hyperimmune intravenous immunoglobulin
(hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available …

Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …

Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …

Intravenous immunoglobulin (IVIg) therapy has been suggested as a potential treatment
option for hospitalised COVID‐19 patients. The aim of this systematic review and meta …

Background It is unknown whether convalescent immunoglobulins (cIgGs) are better than
convalescent plasma (CP) for patients with coronavirus 2019 (COVID-19). Methods In this …

The objective of this study was to assess whether convalescent plasma therapy could offer
survival advantages for patients with novel coronavirus disease 2019 (COVID-19). An …

Background: To date, there has been little agreement on what drug is the" best" drug for
treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of …

COVID-19 pandemic is a global public health emergency. Despite extensive research, there
are still few effective treatment options available today. Neutralizing-antibody-based …